BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 16469347)

  • 21. Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes.
    Saade F; Buronfosse T; Pradat P; Abdul F; Cova L
    Vaccine; 2008 Sep; 26(40):5159-64. PubMed ID: 18554756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes.
    Saade F; Buronfosse T; Guerret S; Pradat P; Chevallier M; Zoulim F; Jamard C; Cova L
    J Viral Hepat; 2013 Apr; 20(4):e56-65. PubMed ID: 23490390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral load in 1-day-old ducklings acutely infected with duck hepatitis B virus by different doses and routes of inoculation.
    Chen ZY; Cheng AC; Wang MS; Xu DW; Jia R; Guo YF; Zeng W
    Avian Pathol; 2009 Apr; 38(2):129-34. PubMed ID: 19322711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Inhibitory effect of trisodium phosphonoformate (PFA) on duck hepatitis B virus (DHBV) DNA in vivo].
    Chen X; Chen H
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):277-81. PubMed ID: 15617348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic neoplasms in aflatoxin B1-treated, congenital duck hepatitis B virus-infected, and virus-free pekin ducks.
    Cullen JM; Marion PL; Sherman GJ; Hong X; Newbold JE
    Cancer Res; 1990 Jul; 50(13):4072-80. PubMed ID: 1972346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation.
    Khawaja G; Buronfosse T; Jamard C; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans C; Hartmann D; Cova L
    Virology; 2012 Mar; 425(1):61-9. PubMed ID: 22284894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anti-virus effect of hepatocyte stimulating substance (HSS) on duck hepatitis B virus in vivo].
    Chen G; Chen J; Liu D; Zhang X; Zhu C; Li Y; Wang L; Yang Y; Cai G; Han F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Dec; 11(4):329-32. PubMed ID: 15617240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IFN-gamma increases efficiency of DNA vaccine in protecting ducks against infection.
    Long JE; Huang LN; Qin ZQ; Wang WY; Qu D
    World J Gastroenterol; 2005 Aug; 11(32):4967-73. PubMed ID: 16124047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single B or T-cell epitope-based DNA vaccine using modified vector induces specific immune response against hepadnavirus.
    Xu HB; Xu W; Chu YW; Wang Y; Xiong S
    Immunol Lett; 2005 Jul; 99(2):186-92. PubMed ID: 16009269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Study on the replication of hepatitis B virus compared with that of duck hepatitis B virus in primary duck hepatocytes].
    Yao Y; Tang N; Huang A
    Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1157-61. PubMed ID: 11769700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experimental study on pathogenicity of precore mutants in Hepadnaviridae.
    Ma Z; Wen Y; Xiong S; Zhai W; He L; Yao X
    Chin Med J (Engl); 1998 Jun; 111(6):519-23. PubMed ID: 11245071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological responsiveness of Pekin ducks to core antigen of duck hepatitis B virus.
    Heermann KH; Wagenseil D; Lottmann S; Gerlich WH; Thomssen R
    Intervirology; 1995; 38(6):316-24. PubMed ID: 8880381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.
    Thermet A; Buronfosse T; Werle-Lapostolle B; Chevallier M; Pradat P; Trepo C; Zoulim F; Cova L
    J Gen Virol; 2008 May; 89(Pt 5):1192-1201. PubMed ID: 18420797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antisense oligodeoxynucleotide targeted at the pre-s region of DHBV could inhibit virus replication in vivo].
    He L; Wu X; Chen C
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Mar; 12(1):1-4. PubMed ID: 12515159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection.
    Soni PN; Brown D; Saffie R; Savage K; Moore D; Gregoriadis G; Dusheiko GM
    Hepatology; 1998 Nov; 28(5):1402-10. PubMed ID: 9794928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of duck hepatitis B virus isolates from South African ducks.
    Mangisa NP; Smuts HE; Kramvis A; Linley CW; Skelton M; Tucker TJ; De La M Hall P; Kahn D; Jilbert AR; Kew MC
    Virus Genes; 2004 Mar; 28(2):179-86. PubMed ID: 14976417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duck hepatitis B virus infection and duck hepatocellular carcinoma.
    Yang GX; Wang QY; Jin YN; Chi BR; Li JM; Ye WF
    Chin Med J (Engl); 1992 Mar; 105(3):217-26. PubMed ID: 1327668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The effect of ribozyme RzDS on duck hepatitis B virus].
    Li H; Chen W; Xu W
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Jun; 12(2):118-21. PubMed ID: 12515186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.
    Foster WK; Miller DS; Scougall CA; Kotlarski I; Colonno RJ; Jilbert AR
    J Virol; 2005 May; 79(9):5819-32. PubMed ID: 15827196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures.
    Civitico GM; Locarnini SA
    Virology; 1994 Aug; 203(1):81-9. PubMed ID: 8030288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.